One infrastructure. Three audiences.
Better pain care starts with better evidence. Celéri Health builds the data backbone that connects medtech and pharma sponsors, clinician-researchers, and payer organizations around the same governed real-world outcomes — functional improvement, opioid reduction, and downstream cost.
Commercial, clinical and regulatory teams draw from the same evidence base — not parallel extracts.
Every engagement runs on 21 CFR Part 11-ready, HIPAA-governed infrastructure from the first enrollment.
Practice registry, sponsored program, regulatory cohort and peer-reviewed manuscript on one platform.
Built for what each team actually has to prove.
The same infrastructure, configured to the evidence question in front of you — whether that question is a label expansion, a first-author publication, or a coverage decision.
Accelerate product innovation and market access
Sponsors need real-world evidence that is timely, regulatory-grade, and payer-ready. Celéri Health turns registries into live evidence programs that sit inside routine clinical care — supporting submissions, label expansion, and value demonstration without a traditional study build.
- Governed evidence registry operational in approximately eight weeks
- Commercial and medical affairs on one dataset
- Regulatory-grade cohort activated on the same patients, no rebuild
Run publication-grade research from your own practice
Community practice is where the innovation happens, but research too often stalls under institutional overhead. Celéri Health lets you build a registry from the care you already deliver, capture longitudinal outcomes without added staff burden, and take investigator-initiated work through to publication.
- Practice registry built from routine encounters
- IRB pathway, protocol and biostatistics support
- Benchmark your outcomes against the wider evidence base
Align reimbursement with outcomes that matter
Randomized trials rarely reflect the members you actually cover. Celéri Health surfaces real-world comparative effectiveness across pain therapies — what reduces pain, restores function, and lowers downstream utilization — so coverage and value-based contracts rest on how treatments perform in practice, not on trial populations that excluded comorbidity.
- Comparative effectiveness across therapies and populations
- Validated PROs alongside utilization and cost signal
- Identify overuse, under-response and true value
One platform. Shared evidence. Better outcomes.
Serving all three audiences on one infrastructure creates something none of them could build alone: a shared evidence base where the same patient encounter answers a commercial question, a scientific question, and a coverage question — without being collected three times.
-
Evidence collected once, used at every tier
The most expensive data in medtech is data gathered twice. A single governed record serves the sponsor's commercial team, the investigator's manuscript, and the payer's coverage review.
-
Effective therapies reach patients sooner
When outcomes are visible in routine practice rather than only in trial cohorts, the case for adoption is made on the population actually being treated.
-
The dataset gets stronger with every encounter
Longitudinal outcomes accumulate across practices, indications and therapies — so benchmarking, feasibility sizing and comparative analysis improve for everyone on the platform.
Find the evidence pathway built for your question.
Whether you're a sponsor approaching launch, a physician building a practice registry, or a payer weighing comparative value — we'll help you scope the right path in a single conversation.
One Platform. Shared Evidence. Better Outcomes.
By serving all stakeholders in pain medicine, Celéri creates a shared evidence base that accelerates adoption of effective therapies, reduces waste, and improves lives. Explore how we can support your goals.
